17
Participants
Start Date
July 31, 2014
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
Oxycodone
One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
Naltrexone
Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
Oxycodone
One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
Naltrexone
Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
Pfizer Investigational Site, Overland Park
Pfizer Investigational Site, Overland Park
Lead Sponsor
Pain Therapeutics
INDUSTRY